Pfizer Reports Positive Mid-Stage Breast Cancer Trial Results [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Pfizer ( PFE Financials ) reported that its experimental breast cancer drug atirmociclib fulfilled the main goal in a mid-stage clinical trial. This is a step forward for its oncology pipeline.The Phase 2 FOURLIGHT-1 trial looked at atirmociclib and fulvestrant together in individuals with advanced or metastatic breast cancer that was hormone receptor-positive and HER2-negative. The research showed that progression-free survival was much better than usual therapy.The trial included 264 people who had already been treated with CDK4/6 inhibitors. Pfizer reported that the medication had a safety profile that was easy to handle, with around 6% of patients stopping treatment because of bad events.Data on overall survival, which is a secondary endpoint, are still not fully developed and will be looked at again in future updates. The business is also doing a Phase 3 experiment to see how well the therapy works as a first-line treatment for metastat
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer Prostate Cancer Data Adds Context To Valuation And Pipeline Outlook [Yahoo! Finance]Yahoo! Finance
- Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLCBusiness Wire
- Pfizer aims for wider use of PARP drug in prostate cancer with new data [Yahoo! Finance]Yahoo! Finance
- The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients [Fortune]Fortune
- TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate CancerBusiness Wire
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 3/16/26 - Form 4
- 3/12/26 - Form ARS
- 3/12/26 - Form DEFA14A
- PFE's page on the SEC website